Lycia Therapeutics is a biotechnology company using its proprietary lysosomal targeting chimera (LYTAC) platform to discover and develop best-in-class therapeutics that degrade extracellular and membrane-bound proteins. These proteins drive a wide range of difficult-to-treat diseases, including autoimmune and inflammatory conditions. Lycia was established in 2019 in collaboration with academic founder and Nobel Laureate Carolyn Bertozzi, Ph.D., professor of chemistry and HHMI investigator at Stanford University. In May 2024, Lycia Therapeutics completed a $106.6 million Series C financing to advance its pipeline of LYTAC extracellular protein degraders to the clinic. Lycia is headquartered in South San Francisco.
Visit https://lyciatx.com/ for more information.
Lycia Therapeutics is seeking an experienced and highly resourceful Executive Assistant to provide senior-level support to our CEO, CFO, and General Counsel. This is a critical role for someone who thrives in a fast-moving, mission-driven biotech environment and excels at anticipating needs, managing competing priorities, and operating with a high degree of discretion. The ideal candidate brings polished executive support experience, exceptional judgment, and a proactive mindset that drives efficiency across the leadership team.
Board Support and Liaison
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Lycia and other biotech companies have recently noticed an increase in email and social media scams targeting job candidates in our industry. Please note Lycia will post any legitimate job openings directly on our website or through our recruitment partner, Lever. If you wish to verify the legitimacy of a job opening, you may contact us.

At Lycia, we aim to eliminate the source of disease using the power of extracellular protein degradation. Our novel LYTAC therapeutics are designed to bind and remove disease-causing extracellular proteins by directing them into the cell for degradation via the lysosome. Focused initially on autoimmune and inflammatory diseases, our platform addresses gaps in targeting proteins outside the cell, offering new hope to patients who urgently need better options.